Ariad shareholder class action dismissed
This article was originally published in Scrip
Executive Summary
Investors' enthusiasm over a district court dismissing a shareholder class action suit against Ariad Pharmaceuticals was short-lived on 25 March, with shares climbing only 25 cents, or about 3%, before falling 29 cents, or about 3.5%, to close at $8.09.